Tumor Heterogeneity Findings Impact Personalized Medicine Approaches

Treatment paradigms for patients suffering from renal cell carcinoma (RCC) typically include a combination of surgery, chemotherapy or immunotherapy and radiation to fight the disease. When such therapies fail patients with advanced RCC receive everolimus, an mTOR inhibitor. In this application note read how exome sequencing in tumor heterogeneity was carried out, in line with the clinical trial of everolimus, to investigate personalized therapy approaches.